Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder

Manic-depressive (bipolar) illness is a serious psychiatric disorder with a strong genetic predisposition. The disorder is likely to be multifactorial and etiologically complex, and the causes of genetic susceptibility have been difficult to unveil. Lithium therapy is a widely used pharmacological treatment of manic-depressive illness, which both stabilizes the ongoing episodes and prevents relapses. A putative target of lithium treatment has been the inhibition of the myo-inositol monophosphatase (IMPase) enzyme, which dephosphorylates myo-inositol monophosphate in the phosphatidylinositol signaling system. Two genes encoding human IMPases have so far been isolated, namely myo-inositol monophosphatase 1 (IMPA1) on chromosome 8q21.13–21.3 and myo-inositol monophosphatase 2 (IMPA2) on chromosome 18p11.2. In the present study, we have scanned for DNA variants in the human IMPA1 and IMPA2 genes in a pilot sample of Norwegian manic-depressive patients, followed by examination of selected polymorphisms and haplotypes in a family-based bipolar sample of Palestinian Arab proband–parent trios. Intriguingly, two frequent single-nucleotide polymorphisms (−461C>T and −207T>C) in the IMPA2 promoter sequence and their corresponding haplotypes showed transmission disequilibrium in the Palestinian Arab trios. No association was found between the IMPA1 polymorphisms and bipolar disorder, neither with respect to disease susceptibility nor with variation in lithium treatment response. The association between manic-depressive illness and IMPA2 variants supports several reports on the linkage of bipolar disorder to chromosome 18p11.2, and sustains the possible role of IMPA2 as a susceptibility gene in bipolar disorder.

[1]  S. Detera-Wadleigh,et al.  A novel human myo-inositol monophosphatase gene, IMP.18p, maps to a susceptibility region for bipolar disorder , 1997, Molecular Psychiatry.

[2]  Stuart Wilson,et al.  The role of Schizosaccharomyces pombe Rad32, the Mre11 homologue, and other DNA damage response proteins in non-homologous end joining and telomere length maintenance , 1999, Nucleic Acids Res..

[3]  M. Berridge,et al.  Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. , 1982, The Biochemical journal.

[4]  R. Ebstein,et al.  Reduced inositol content in lymphocyte-derived cell lines from bipolar patients. , 2002, Bipolar disorders.

[5]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[6]  W. Blackwood.  Chromosome 18 DNA markers and manic-depressive illness : evidence for a susceptibility gene , 1994 .

[7]  M. Baron,et al.  Manic-depression genes and the new millennium: poised for discovery , 2002, Molecular Psychiatry.

[8]  J. Kleinman,et al.  Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. , 1997, The American journal of psychiatry.

[9]  O. Spleiss,et al.  Differential expression, activity and regulation of the sodium/myo-inositol cotransporter in astrocyte cultures from different regions of the rat brain , 2000, Neuropharmacology.

[10]  C. Ragan,et al.  The purification and properties of myo-inositol monophosphatase from bovine brain. , 1988, The Biochemical journal.

[11]  S. Antonarakis.  Recommendations for a nomenclature system for human gene mutations , 1998 .

[12]  R. Dixon,et al.  Cloning and expression of bovine brain inositol monophosphatase. , 1990, The Journal of biological chemistry.

[13]  M. Slatkin,et al.  On selecting markers for association studies: Patterns of linkage disequilibrium between two and three diallelic loci , 2003, Genetic epidemiology.

[14]  J. Parrish,et al.  Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. , 1999, The American journal of psychiatry.

[15]  P. Sham,et al.  Faster Haplotype Frequency Estimation Using Unrelated Subjects , 2002, Human Heredity.

[16]  A. Harwood,et al.  A common mechanism of action for three mood-stabilizing drugs , 2002, Nature.

[17]  R. Jope.  Anti-bipolar therapy: mechanism of action of lithium , 1999, Molecular Psychiatry.

[18]  M. Wolfson,et al.  Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations , 2000, Brain Research.

[19]  R. Straub,et al.  Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. , 2002, American journal of human genetics.

[20]  W. Sherman,et al.  The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. , 1980, The Journal of biological chemistry.

[21]  R. Ebstein,et al.  Effect of bipolar disorder on lymphocyte inositol monophosphatase mRNA levels. , 1999, The international journal of neuropsychopharmacology.

[22]  R. Ebstein,et al.  Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy , 1998, Molecular Psychiatry.

[23]  V. Steen,et al.  Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. , 1996, Pharmacogenetics.

[24]  S. Detera-Wadleigh,et al.  Genomic structure and novel variants of myo-inositol monophosphatase 2 (IMPA2) , 2000, Molecular Psychiatry.

[25]  D. Clayton,et al.  Transmission/disequilibrium tests for extended marker haplotypes. , 1999, American journal of human genetics.

[26]  G. Kirov,et al.  The Wellcome trust UK–Irish bipolar affective disorder sibling-pair genome screen: first stage report , 2002, Molecular Psychiatry.

[27]  H. Manji,et al.  Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manic-depressive illness. , 1999, The Australian and New Zealand journal of psychiatry.

[28]  J. Kennedy,et al.  Altered IMPA2 gene expression and calcium homeostasis in bipolar disorder , 2001, Molecular Psychiatry.

[29]  J. Sikela,et al.  Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA). , 1997, Genomics.

[30]  W. Berrettini.  Molecular linkage studies of bipolar disorders. , 2001, Bipolar disorders.

[31]  D. Botstein,et al.  Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. , 1995, American journal of human genetics.

[32]  D. Calker,et al.  Inhibition of the High Affinity Myo-Inositol Transport System: A Common Mechanism of Action of Antibipolar Drugs? , 1999, Neuropsychopharmacology.

[33]  S. Detera-Wadleigh,et al.  Map of candidate genes and STSs on 18p11.2, a bipolar disorder and schizophrenia susceptibility region , 2002, Molecular Psychiatry.

[34]  Y. Okubo,et al.  Evidence for association of the myo-inositol monophosphatase 2 (IMPA2) gene with schizophrenia in Japanese samples , 2001, Molecular Psychiatry.

[35]  Michael J. Berridge,et al.  Neural and developmental actions of lithium: A unifying hypothesis , 1989, Cell.

[36]  P. Majerus,et al.  Properties of inositol polyphosphate 1-phosphatase. , 1988, The Journal of biological chemistry.

[37]  W. Ewens,et al.  Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). , 1993, American journal of human genetics.

[38]  W. Sherman,et al.  Increased brain myo-inositol 1-phosphate in lithium-treated rats. , 1976, Biochemical and biophysical research communications.

[39]  C. Phiel,et al.  Molecular targets of lithium action. , 2003, Annual review of pharmacology and toxicology.

[40]  S. Cichon,et al.  Evaluation of linkage of bipolar affective disorder to chromosome 18 in a sample of 57 German families , 1999, Molecular Psychiatry.

[41]  L R Goldin,et al.  A high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  W. Maier,et al.  Support for a chromosome 18p locus conferring susceptibility to functional psychoses in families with schizophrenia, by association and linkage analysis. , 1998, American journal of human genetics.

[43]  A. Molven,et al.  A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients , 2000, Molecular Psychiatry.

[44]  J. Nurnberger,et al.  Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.